Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Divio Technologies genomför riktad nyemission

· Styrelsen i Divio Technologies AB har beslutat att genomföra en riktad nyemission av 11,11 miljoner B-aktier till emissionskursen 0,45 SEK, som tillför bolaget 5 miljoner SEK.  · Nyemissionen ska möjliggöra accelererade försäljningsprocesser mot stora, långsiktigt lönsamma kunder.Jon Levin, VD i Divio Technologies, kommenterar: Vårt fokus är att prioritera försäljningsprocessen mot stora, långsiktigt mer lönsamma kunder. Vi har redan Fidelity och ett antal andra större kunder och vår målsättning är att utveckla samma kundrelation med andra bolag av samma dignitet. Vi tror att vi är på

Flexion Mobile signs Battle Warship from Special Gamez

Another top tier game signing from Flexion's team in ChinaLONDON, 30th of June, 2020 – Flexion Mobile Plc (Nasdaq: FLEXM), the Android games distribution company today announced that it has signed an agreement  with a new developer called Special Gamez for Battle Warship Naval Empire. In May, the top tier game generated USD 3 million net revenue in Google Play according to data analyst Sensor Tower. The game is expected to launch this summer and the agreement covers all Flexion main channels Amazon, Huawei, ONE Store and Samsung.  "This game is a classic naval war game that we have been

Selumetinib granted orphan drug designation in Japan for neurofibromatosis type 1

30 June 2020 07:00 BST Selumetinib granted orphan drug designation in Japan for neurofibromatosis type 1 Designation follows recent US approval with additional regulatory submissions underway Phase II SPRINT trial showed selumetinib reduced tumourvolume in paediatric patients with NF1 plexiform neurofibromas AstraZeneca today announced that selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1), a rare and debilitating genetic disease.[1] Selumetinib is co-developed and co-commercialised with MSD Inc.,

New number of shares and votes in Moberg Pharma AB (publ)

STOCKHOLM, June 30[th] 2020. During June 2020, the registered number of shares and votes in Moberg Pharma AB (OMX: MOB) (“Moberg Pharma” or the “Company”) has increased due to conversion of convertible notes issued pursuant to the financing agreement entered into between the Company and Nice & Green S.A. on March 23rd, 2020.The total number of shares and votes in the Company has increased as a result of the board of directors’ resolution to approve Nice & Green S.A.’s request to convert a number of convertible notes into a total of 34,430 common shares in the Company, in accordance with the

MAG Interactive AB (publ) publishes Interim Report September – May 2019/2020

Revenue increases by 34% in Q3 compared to the same quarter the previous yearSummary of the period March 2019 – May 2020: · The Group's net sales for the period were 64,838 KSEK (48,311 KSEK), an increase of 34% compared to the same period the previous year · EBITDA for the period was 3,404 KSEK (542 KSEK) · The Group's game contribution for the period was 30,710 KSEK (27,463 KSEK), an increase of 12% compared to the same period the previous year · Average revenue per daily active user, ARPDAU, for the period was 3.0 US cents (2.6 US cents), an increase of 14% compared to the

SciBase announces a Management team change

Anna Danström, SciBase’s head of production and supply chain, has chosen to leave her position and accept a role at another company. Linn Olsen will replace Anna as production and supply chain manager. Linn has a broad background within production, QA and Medtech, and comes from Trimble.  ”I would like to take the opportunity to thank Anna for her exceptional work at SciBase, and especially at our Uppsala facility. Anna has ensured that we have a well-functioning electrode manufacturing process and team and has also played a key role in improving our electrode gross margin. I wish Anna

Hansa Biopharma to host conference call to provide interim results for the first half of 2020 and business update

Lund, Sweden June 30, 2020. Hansa Biopharma will publish its interim report for January-June 2020 at 8:00 a.m. CET on July 16, 2020. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 2:00 p.m. CET. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English. Slides used in the presentation will be live on the company website during the call under “Events & Webcast,” and will also be made

Completed transactions and construction starts during the first half of 2020

During the first half of 2020, Wallenstam started the construction of almost 400 apartments in two projects, in Gothenburg and Mölnlycke. In addition, several transactions and agreements were completed that will enable future new production.The construction starts involve 267 rental apartments in Kv.8, part of the urban development project Kallebäcks Terraser in Gothenburg and 116 rental apartments in the Väven block, part of the urban development project Mölnlycke Fabriker in Härryda Municipality. All 383 apartments are planned to be ready for occupation during 2022. In March,

Inhalation Sciences: key patent approved in Europe

(Stockholm, 30 June 2020) Inhalation Sciences (ISAB) has received European approval, with no restrictions, for a key patent that covers the company’s unique simplified method to accomplish so called “regional targeting”— or being able to selectively direct aerosol exposures to the different main regions in the lung.Regional targeting gives new opportunities to map how either drug substances or air pollutants work in the lungs. The patent with reference number EP2173419 has previously been approved in the US and China, but is now also approved on the important European market without

Presentation of Gränges’ half-year report for January–June 2020

Gränges’ half-year report for the period January–June 2020 will be published at 07.30 CEST on Thursday, 16 July 2020. The webcast will be available on www.granges.com/investors. To participate in the conference call, please call +46 8 56642651 (Sweden), +44 3333000804 (United Kingdom) or +1 6319131422 (United States). PIN code: 69788601#. Please call a few minutes before the conference call begins. A presentation will be available on the company’s website before the webcast begins. For further information, please contact:Johan Dufvenmark, VP Group Treasury & Investor Relations

Change in the total number of shares and votes in Recipharm AB (publ)

As of 30 June 2020, the total number of shares in Recipharm AB (publ) (“Recipharm”) amounts to 100,990,187 shares, divided into 21,311,998 shares of series A and 79,678,189 shares of series B. The total number of votes in Recipharm as of 30 June 2020 amounts to 292,798,169. The number of shares and votes in Recipharm has increased as a result of the registration of 6,089,140 shares of series A and 22 600 368 shares of series B subscribed for by the exercise of subscription rights in the ongoing rights issue in Recipharm, which was resolved on May 26, 2020.  For more information

Positive results from human PK study assessing Orexo’s intranasal nalmefene formulations for opioid overdose reversal

· Preliminary data indicate extensive and rapid absorption of OX125 across all formulations · Positive results underline the applicability of Orexo’s novel intranasal drug delivery platform Uppsala, Sweden - June 30, 2020 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces positive results from its human pharmacokinetic (PK) study of OX125. The study was a cross-over, comparative bioavailability study in healthy volunteers to assess nalmefene absorption from three development formulations of OX125, Orexo's wholly-owned nasal nalmefene product, compared to a nalmefene

Conversion of shares

According to Essity’s articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in the company. When such a conversion has occurred, the company is obligated by law to disclose any such changes in this manner.In June, at the request of shareholders 1,912,497 Class A shares were converted to Class B shares. The total number of votes in the company thereafter amounts to 1,257,975,156.The total number of registered shares in the company amounts to 702,342,489 of which 61,736,963 are Class A

Oncopeptides submits a New Drug Application to the FDA for accelerated approval of melflufen in triple-class refractory multiple myeloma patients

STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company submits a New Drug Application (NDA) to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen (INN melphalan flufenamide) in combination with dexamethasone for the treatment of adult patients with multiple myeloma whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody (i.e., triple-class refractory multiple myeloma patients).Melflufen is the lead candidate coming out of the

Starbreeze resolves on a fully guaranteed rights issue of SEK 250 million to enable full focus on continued development of PAYDAY 3 and strengthening financial position

The Board of Directors of Starbreeze AB (publ) (“Starbreeze” or the “Company”) has today resolved on a rights issue of class A and class B shares of approximately SEK 250 million before transaction costs (the “Rights Issue”). The proceeds from the Rights Issue will be used to strengthen the financial position and for operational purposes, enabling the Company to fully focus on continued development of PAYDAY 3, and support the Company to fulfil its obligations to its creditors in line with the reorganization plan and the judicial composition. The Rights Issue is supported by the Company’s

Lindab will close down IMP Klima Group

Production of large air handling units will be discontinued After a strategic performance review, Lindab has today decided to close down IMP Klima Group, consisting of LINDAB, klima sistemi, d.o.o. in Slovenia and its subsidiaries in Serbia, Montenegro and Bosnia-Herzegovina. The production of air handling units in Slovenia will be discontinued by the end of 2020. Lindab acquired IMP Klima in 2015 to establish a presence in the air handling unit market. It is a highly competitive market with customized solutions. IMP Klima has shown poor sales development and it has been a loss-making

Order worth 6 million SEK for Tier1 supplier in USA

FlexQube has received an order for a German based company, who is setting up a new plant to manufacture automotive parts in Southeast USA, worth 6 million SEK. The order consists of modular FlexQube trolleys in four different versions in combination with the Liftrunner Mother Daughter tugger train system. IPW Lift Techs is managing the deal and FlexQube is selling the products through them. The order will be delivered during the third quarter 2020. “Once again we win a large tugger train order after showing the customer how strong the combination of the unique and modular FlexQube

SSM acquires all shares in half-owned JV company Studentbacken including ca 280 building rights in Bromma, Sollentuna and Täby

SSM Holding AB, Sweden’s leading residential developer within smart, affordable homes, has acquired all of the shares in the half-owned joint venture company Studentbacken that SSM has run together with Student Hill since 2013. The acquisition also includes about 280 building rights in three projects currently being developed within the joint venture: Kandidaten, The Loft and Tentafabriken. The purchase price amounts to ca 2.0 MSEK and the transaction will be carried out in July 2020.Today, SSM has acquired all of the shares in the half-owned joint venture company Studentbacken.Since 2013,

Konftel receives Frost & Sullivan award for best video-capable conference product

Konftel , a global leader in products for effective distance meetings, has been presented with a Best Practices Award by the distinguished US analysis firm Frost & Sullivan. The award relates to the company’s Konftel 800 conference phone, which delivers outstanding sound in video conferences. Frost & Sullivan judges the Konftel C50800 Hybrid video package to be the most attractive option on the market.“Considering the generous specifications and sturdy build quality, Frost & Sullivan believes the Konftel C50800 Hybrid audio-video bundle offers the best value for

Gasum opened a new shipping fuel station at Ports of Stockholm

Gasum’s new bunkering station for liquefied gas was taken into use in mid-June. The station is located at Port of Nynäshamn, Sweden on the premises of Ports of Stockholm. The new station includes new bunkering solutions enabling ships to bunker environmentally friendly fuel faster than ever.After a year of construction, the new bunkering station is finally ready to serve existing and new customers. It enables bunkering at high speed from two trucks at the same time. The station set-up and the specialized trucks now being used allows bunkering to take place at the same time as unloading or

Change of number of shares and votes in Green Landscaping Group AB (publ)

In June 2020, the number of shares and votes in Green Landscaping Group AB (publ) ("Green Landscaping" or the “Company") has changed as a result of the rights issue carried out by Green Landscaping in order to strengthen the Company's balance sheet by repaying the bridge financing raised in connection with the acquisition of GAST Entreprenør AS and P.A.R.K. i Syd AB and to increase the Company's cash and cash equivalents in readiness for future acquisitions. Through the rights issue, the number of shares and votes in Green increased by 9,236,026. As of 30 June 2020, there is in total 46,

Nordic Nanovector to amend PARADIGME trial protocol to expand eligible patient population

Oslo, Norway, 30 June 2020 Nordic Nanovector ASA (OSE: NANO) announces that it will amend the trial protocol for its PARADIGME trial to broaden the inclusion criteria and expand the pool of eligible patients with the aim of increasing the present rate of enrolment. This decision has been made based on the company’s reviewed discussions with the US Food and Drug Administration (FDA). PARADIGME is the company’s ongoing pivotal, global, randomised Phase 2b trial investigating Betalutin® ([177]Lu-lilotomab satetraxetan) as a single administration in 3[rd]-line relapsed/refractory

There are no items matching the current filter
There are no more items matching the current filter
Back to top